Respiratory

The UK group began more clinical trials last year than any other company, a new report from Citeline has found.

Until the full data are released, it is difficult to weigh ANCHOR.

The Avillion-partnered treatment has succeeded in the BATURA trial, adding to the body of evidence supporting Airsupra as a first-in-class rescue treatment and its role in reducing the risk of asthma exacerbations in patients regardless of disease severity.

The Swedish company is well positioned, and well financed with a bit of help from the French major, to push its idiopathic pulmonary fibrosis hopeful buloxibutid closer to the regulatory finishing line.

The IL-4/13 inhibitor was approved in the US for COPD, a blockbuster-sized indication, but the commercial ramp could take time and several competitors are on its heels. 

While it waits to see if Fasenra succeeds in a Phase III trial for chronic obstructive pulmonary disease, the UK major has got over the regulatory line in the much smaller but underserved space of eosinophilic granulomatosis with polyangiitis.

Nerandomilast improved patients’ lung function to a greater degree than placebo, but safety data will be key.    

The company announced the launch of a new “vant” subsidiary focused on development of mosliciguat for pulmonary hypertension associated with interstitial lung disease.

GSK’s ultra-long-acting biologic cuts asthma attacks, but misses on all the secondary endpoints in the twin SWIFT trials could limit its appeal.    

The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients who had suffered moderate or severe exacerbations in the previous year.

Nucala finally succeeds in a COPD Phase III study by narrowing its target patients, setting it up to compete in a huge new market to be led by Sanofi’s Dupixent.

The recent sale of Karuna to Bristol Myers Squibb for $14bn is "a great case study for our model and a hallmark of how we create value both clinically and financially," Bharatt Chowrira told analysts on PureTech's first-half business update.

ARS will compete directly with EpiPen and other injectable products with inhaled neffy as the first needle-free epinephrine therapy for severe allergy attacks. EU approval is thought imminent.

Second quarter revenues are up but RSV jab woes drag on the company’s stock.    

The deal includes up to 10 medicines, with an initial focus on immunology and respiratory diseases, and is similar to one the VC firm made with Pfizer last year.

With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.    

The French drugmaker can now boast seven approvals for its huge-earning IL-4/IL-13 inhibitor.

The respiratory specialist is set to hit the ground running with Ohtuvayre, the first COPD inhaled product with a novel mechanism of action to be approved in over two decades.

Five years after a Phase III failure, Savara reports pivotal data supporting approval of molgramostim as the first drug for autoimmune pulmonary alveolar proteinosis.

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.